Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 14/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 2/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3181081 | 0.81 | PTPN1 (0.47) | PTPN1PTPN2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL3201488 | 0.77 | PTGER4 (0.41) | KDM4EPTGER4 | |
| SCHEMBL13926049 | 0.75 | IKBKB (0.50) | PTPN1PTPN2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL3193789 | 0.75 | PTPN1 (0.51) | PTPN1PTPN2PTPRC | |
| SCHEMBL3194810 | 0.73 | PTPN1 (0.61) | PTPN1PTPN2KDM4EPTPRC | |
| SCHEMBL4118791 | 0.73 | PTPN1 (0.47) | PTPN1PTPN2KDM4EPKMHTT | |
| SCHEMBL4118782 | 0.71 | PTPN1 (0.61) | PTPN1PTPN2KDM4EPTPRC | |
| SCHEMBL13926050 | 0.69 | MCL1 (0.57) | PTPN1PTPN2KDM4EPTPRC | |
| SCHEMBL2059355 | 0.69 | CSNK2A2 (0.49) | CSNK2A2CSNK2BCSNK2A1KDM4E | |
| SCHEMBL3191306 | 0.67 | PTPN1 (0.52) | PTPN1PTPN2KDM4EPTPRCHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674822-B2 | protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid | WYETH (US) | 2010-03-09 | — | — | US | disclosed |
| US-20060135488-A1 | protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid | WYETH | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135488-A1 | protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid | PTPA, PTPRCAP, PTPRC | PTPN1 22/4885PTPN2 14/4885CSNK2A2 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.